C34T AMP Deaminase 1 gene mutation protects cardiac function in donors

Transplantation

Volumn 77, Issue 10, 2004, Pages 1621-1623

  Yacoub, Magdi H ^a   Yuen, Ada H Y ^a   Kalsi, Kameljit K ^a   Birks, Emma J ^a   Taegtmeyer, Anne ^a   Barton, Paul J ^a   Johnson, Philip H ^a   Suzuki, Ken ^a   Smolenski, Ryszard T ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE MONOPHOSPHATE DEAMINASE; ADENOSINE MONOPHOSPHATE DEAMINASE 1; CYTOSINE; THYMINE; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEART DISEASE; HEART FAILURE; HEART PROTECTION; HEART TRANSPLANTATION; HEREDITY; HUMAN; MALE; MUTATION RATE; NONSENSE MUTATION; ORGAN DONOR; PRIORITY JOURNAL; PROTECTION; SCHOOL CHILD; SINGLE STRAND CONFORMATION POLYMORPHISM; SURVIVAL;

AMP DEAMINASE; CARDIAC OUTPUT, LOW; CHRONIC DISEASE; CYTOSINE; HEART; HUMANS; MUTATION; THYMINE; TISSUE DONORS;

EID: 2542540489     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000122413.46512.05     Document Type: Article

References (12)

1. Emery RW, Cork RC, Levinson MM, et al. The cardiac donor: a six-year experience. Ann Thorac Surg 1986; 41: 356-362.
2. Birks EJ, Yacoub MH, Burton PS, et al. Activation of apoptotic and inflammatory pathways in dysfunctional donor hearts. Transplantation 2000; 70: 1498-1506.
3. Loh E, Rebbeck TR, Mahoney PD, et al. Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circ 1999; 99: 1422-1425.
4. Anderson JL, Habashi J, Carlquist JF, et al. A common variant of the AMPD1 gene predicts improved cardiovascular survival in patients with coronary artery disease. J Am Coll Cardiol 2000; 36: 1248-1252.
5. Morisaki T, Gross M, Morisaki H, et al. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci USA 1992; 89: 6457-6461.
6. Smolenski RT, Raisky O, Slominska EM, et al. Protection from reperfusion injury after cardiac transplantation by inhibition of adenosine metabolism and nucleotide precursor supply. Circ 2001; 104: I246-I252.
7. Wang X, Morisaki H, Sermsuvitayawong K, et al. Cloning and expression of cDNA encoding heart-type isoform of AMP deaminase. Gene 1997; 188: 285-290.
8. Kalsi KK, Yuen AH, Rybakowska IM, et al. Decreased cardiac activity of AMP deaminase in subjects with the AMPD1 mutation-A potential mechanism of protection in heart failure. Cardiovasc Res 2003; 59: 678-684.
9. Saks VA, Kapelko VI, Kupriyanov VV, et al. Quantitative evaluation of relationship between cardiac energy metabolism and post-ischemic recovery of contractile function. J Mol Cell Cardiol 1989; 21 (Suppl 1): 67-78.
10. Smolenski RT, Simmonds HA, Chambers DJ. Exogenous adenosine supplied transiently during reperfusion ameliorates depressed endogenous adenosine production in the post-ischemic rat heart. J Mol Cell Cardiol 1997; 29: 333-346.
11. Peralta C, Bartrons R, Serafin A, et al. Adenosine monophosphate-activated protein kinase mediates the protective effects of ischemic preconditioning on hepatic ischemia-reperfusion injury in the rat. Hepatology 2001; 34: 1164-1173.
12. Hopkins TA, Dyck JR, Lopaschuk GD. AMP-activated protein kinase regulation of fatty acid oxidation in the ischaemic heart. Biochem Soc Trans 2003; 31: 207-212.